Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 13/20 | 0.53 |
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
| ▸ | L3MBTL3 | Q96JM7 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.48 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.48 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5209386 | 0.86 | KMT2A (0.57) | HRH3HRH1L3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL5210119 | 0.85 | HRH3 (0.55) | HRH3HRH1L3MBTL3L3MBTL1MBTD1 | |
| Hydrochloric Acid SCHEMBL5213050 | 0.85 | KMT2A (0.56) | HRH3HRH1L3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL5210695 | 0.83 | HRH3 (0.53) | HRH3HRH1L3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL5209775 | 0.83 | HRH3 (0.53) | HRH3HRH1L3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL5208660 | 0.82 | HRH3 (0.55) | HRH3HRH1L3MBTL3L3MBTL1MBTD1 | |
| Hydrochloric Acid SCHEMBL5213593 | 0.82 | HRH3 (0.52) | HRH3HRH1L3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL5209549 | 0.81 | L3MBTL3 (0.70) | HRH3HRH1L3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL5212856 | 0.81 | L3MBTL3 (0.68) | HRH3HRH1L3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL5208300 | 0.79 | L3MBTL3 (0.62) | HRH3HRH1L3MBTL3L3MBTL1MBTD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1646620-B1 | SUBSTITUTED PIPERIDINES AS HISTAMINE H3 RECEPTOR LIGANDS | GLAXO GROUP LTD (GB) | 2007-08-15 | — | — | EP | claimed |
| EP-1646620-B1 | SUBSTITUTED PIPERIDINES AS HISTAMINE H3 RECEPTOR LIGANDS | GLAXO GROUP LTD (GB) | 2007-08-15 | — | — | EP | disclosed |
| EP-1646620-B1 | SUBSTITUTED PIPERIDINES AS HISTAMINE H3 RECEPTOR LIGANDS | GLAXO GROUP LTD (GB) | 2007-08-15 | — | — | EP | disclosed |
| US-20060247227-A1 | Substituted piperidines as histamine h3 receptor ligands | BAILEY JAMES M | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247227-A1 | Substituted piperidines as histamine h3 receptor ligands | HRH3, HRH4, HRH1 | HRH3 1/4885HRH1 3/4885L3MBTL3 3618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.